Cover Image
Market Research Report
Product code 
1076817

Cancer/Tumor Profiling Market Research Report by Technology, Cancer Type, Biomarker Type, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Published: | 360iResearch LLP | 214 Pages | Delivery time: 1-2 business days

Price

Back to Top
Cancer/Tumor Profiling Market Research Report by Technology, Cancer Type, Biomarker Type, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: May 12, 2022
360iResearch LLP
Content info: 214 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Global Cancer/Tumor Profiling Market size was estimated at USD 9,872.31 million in 2021 and expected to reach USD 11,656.24 million in 2022, and is projected to grow at a CAGR 18.32% to reach USD 27,094.28 million by 2027.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Cancer/Tumor Profiling to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Technology, the market was studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, Others, and Polymerase Chain Reaction.

Based on Cancer Type, the market was studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, Other, and Prostate Cancer.

Based on Biomarker Type, the market was studied across Genomic Biomarker and Protein Biomarker.

Based on Application, the market was studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cancer/Tumor Profiling market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer/Tumor Profiling Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer/Tumor Profiling Market, including Agendia, Inc., Boreal Genomics Inc, Caris Life Sciences, Foundation Medicine, Genomic Health Inc., GenScript Biotech Corporation, Guardant Health, Inc., Helomics Corporation, HistoGeneX NV, HTG Molecular Diagnostics, Inc., Illumina, Inc., NanoString Technologies, Inc., NeoGenomics Laboratories, Inc., Omniseq, Inc., Perthera, Inc., QIAGEN N.V., Ribomed Biotechnologies, Inc., Roche Diagnostics, Sysmex Corporation, and Tempus Labs.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Cancer/Tumor Profiling Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer/Tumor Profiling Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer/Tumor Profiling Market?
  • 4. What is the competitive strategic window for opportunities in the Global Cancer/Tumor Profiling Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Cancer/Tumor Profiling Market?
  • 6. What is the market share of the leading vendors in the Global Cancer/Tumor Profiling Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Cancer/Tumor Profiling Market?
Product Code: MRR-374DB5A06C9C

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising funding from government for devising cancer diagnosing methods
      • 5.1.1.2. Increasing incidence of cancer
      • 5.1.1.3. Increasing use of biomarkers in cancer profiling
    • 5.1.2. Restraints
      • 5.1.2.1. High capital investment in Cancer/Tumor Profiling devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing demand for personalized medicine
      • 5.1.3.2. Growing need for point-of-care diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Low biomarker discovery-to-approval ratio
  • 5.2. Cumulative Impact of COVID-19

6. Cancer/Tumor Profiling Market, by Technology

  • 6.1. Introduction
  • 6.2. Immunoassays
  • 6.3. In-Situ Hybridization
  • 6.4. Mass Spectrometry
  • 6.5. Microarrays
  • 6.6. Next-Generation Sequencing
  • 6.7. Others
  • 6.8. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Lung Cancer
  • 7.5. Melanoma Cancer
  • 7.6. Other
  • 7.7. Prostate Cancer

8. Cancer/Tumor Profiling Market, by Biomarker Type

  • 8.1. Introduction
  • 8.2. Genomic Biomarker
  • 8.3. Protein Biomarker

9. Cancer/Tumor Profiling Market, by Application

  • 9.1. Introduction
  • 9.2. Biomarker Discovery
  • 9.3. Clinical Application
  • 9.4. Diagnostics
  • 9.5. Personalized Medicine
  • 9.6. Prognostics
  • 9.7. Research
  • 9.8. Screening
  • 9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

  • 12.1. Introduction
  • 12.2. France
  • 12.3. Germany
  • 12.4. Italy
  • 12.5. Netherlands
  • 12.6. Qatar
  • 12.7. Russia
  • 12.8. Saudi Arabia
  • 12.9. South Africa
  • 12.10. Spain
  • 12.11. United Arab Emirates
  • 12.12. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
    • 13.1.1. Quadrants
    • 13.1.2. Business Strategy
    • 13.1.3. Product Satisfaction
  • 13.2. Market Ranking Analysis
  • 13.3. Market Share Analysis, By Key Player
  • 13.4. Competitive Scenario
    • 13.4.1. Merger & Acquisition
    • 13.4.2. Agreement, Collaboration, & Partnership
    • 13.4.3. New Product Launch & Enhancement
    • 13.4.4. Investment & Funding
    • 13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles

  • 14.1. Agendia, Inc.
  • 14.2. Boreal Genomics Inc
  • 14.3. Caris Life Sciences
  • 14.4. Foundation Medicine
  • 14.5. Genomic Health Inc.
  • 14.6. GenScript Biotech Corporation
  • 14.7. Guardant Health, Inc.
  • 14.8. Helomics Corporation
  • 14.9. HistoGeneX NV
  • 14.10. HTG Molecular Diagnostics, Inc.
  • 14.11. Illumina, Inc.
  • 14.12. NanoString Technologies, Inc.
  • 14.13. NeoGenomics Laboratories, Inc.
  • 14.14. Omniseq, Inc.
  • 14.15. Perthera, Inc.
  • 14.16. QIAGEN N.V.
  • 14.17. Ribomed Biotechnologies, Inc.
  • 14.18. Roche Diagnostics
  • 14.19. Sysmex Corporation
  • 14.20. Tempus Labs

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER/TUMOR PROFILING MARKET: DYNAMICS
  • FIGURE 2. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (%)
  • FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (USD MILLION)
  • FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2027
  • FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, 2019-2027 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, 2019-2027 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, 2019-2027 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, 2019-2027 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2019-2027 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY OTHERS, 2019-2027 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY OTHERS, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2019-2027 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2021 VS 2027 (%)
  • FIGURE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2021 VS 2027 (USD MILLION)
  • FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2027
  • FIGURE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2019-2027 (USD MILLION)
  • FIGURE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2019-2027 (USD MILLION)
  • FIGURE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, 2019-2027 (USD MILLION)
  • FIGURE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, 2019-2027 (USD MILLION)
  • FIGURE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY OTHER, 2019-2027 (USD MILLION)
  • FIGURE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY OTHER, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 32. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, 2019-2027 (USD MILLION)
  • FIGURE 33. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2021 VS 2027 (%)
  • FIGURE 35. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2021 VS 2027 (USD MILLION)
  • FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2027
  • FIGURE 37. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, 2019-2027 (USD MILLION)
  • FIGURE 38. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, 2019-2027 (USD MILLION)
  • FIGURE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 41. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
  • FIGURE 42. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
  • FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2027
  • FIGURE 44. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, 2019-2027 (USD MILLION)
  • FIGURE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 46. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2019-2027 (USD MILLION)
  • FIGURE 47. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 48. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
  • FIGURE 49. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, 2019-2027 (USD MILLION)
  • FIGURE 51. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, 2019-2027 (USD MILLION)
  • FIGURE 53. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 54. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, 2019-2027 (USD MILLION)
  • FIGURE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 56. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, 2019-2027 (USD MILLION)
  • FIGURE 57. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 58. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, 2019-2027 (USD MILLION)
  • FIGURE 59. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2021 VS 2027 (USD MILLION)
  • FIGURE 60. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 61. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 62. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 63. CANADA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 64. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 65. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 66. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 67. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 68. CHINA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 69. INDIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 70. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 71. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 72. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 73. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 74. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 75. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 76. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 77. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 78. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 79. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 80. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 81. ITALY CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 82. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 83. QATAR CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 84. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 85. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 86. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 87. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 88. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 89. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • FIGURE 90. GLOBAL CANCER/TUMOR PROFILING MARKET: FPNV POSITIONING MATRIX
  • FIGURE 91. GLOBAL CANCER/TUMOR PROFILING MARKET: SHARE, BY KEY PLAYER, 2021
  • FIGURE 92. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CANCER/TUMOR PROFILING MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER/TUMOR PROFILING MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
  • TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 5. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 6. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 7. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 8. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 10. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 11. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 12. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 13. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 16. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 17. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 18. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 20. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 21. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 22. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 23. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 25. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 26. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 28. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY OTHERS, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 30. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY OTHERS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 31. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY OTHERS, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY OTHERS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 33. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY OTHERS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 35. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 36. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 38. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2019-2027 (USD MILLION)
  • TABLE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 41. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 42. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 44. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 46. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 47. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 51. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 52. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 56. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 57. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 60. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY OTHER, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 61. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY OTHER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 62. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY OTHER, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY OTHER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY OTHER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 65. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 66. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 67. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 70. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2019-2027 (USD MILLION)
  • TABLE 71. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 72. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 73. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 76. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 77. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 78. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 81. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
  • TABLE 82. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 83. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 84. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 87. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 88. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 89. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 92. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 93. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 94. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 97. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 98. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 99. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 102. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 103. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 104. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 107. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 108. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 109. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 112. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 113. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 114. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 117. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 118. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 119. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY STATE, 2019-2027 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 122. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 123. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 124. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 125. CANADA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 126. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 127. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 129. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 130. CHINA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 131. INDIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 132. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 133. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 134. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 135. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 136. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 137. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 138. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 139. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 141. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 142. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 143. ITALY CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 144. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 145. QATAR CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 146. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 147. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 148. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 149. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 150. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 151. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, 2019-2027 (USD MILLION)
  • TABLE 152. GLOBAL CANCER/TUMOR PROFILING MARKET: SCORES
  • TABLE 153. GLOBAL CANCER/TUMOR PROFILING MARKET: BUSINESS STRATEGY
  • TABLE 154. GLOBAL CANCER/TUMOR PROFILING MARKET: PRODUCT SATISFACTION
  • TABLE 155. GLOBAL CANCER/TUMOR PROFILING MARKET: RANKING
  • TABLE 156. GLOBAL CANCER/TUMOR PROFILING MARKET: SHARE, BY KEY PLAYER, 2021
  • TABLE 157. GLOBAL CANCER/TUMOR PROFILING MARKET: MERGER & ACQUISITION
  • TABLE 158. GLOBAL CANCER/TUMOR PROFILING MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 159. GLOBAL CANCER/TUMOR PROFILING MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 160. GLOBAL CANCER/TUMOR PROFILING MARKET: INVESTMENT & FUNDING
  • TABLE 161. GLOBAL CANCER/TUMOR PROFILING MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 162. GLOBAL CANCER/TUMOR PROFILING MARKET: LICENSE & PRICING